Certara, a global biosimulation technology-enabled drug development company, today announced the introduction of Phoenix Technology Services. These services, led and implemented by Certara’s team of biosimulation (modeling and simulation) experts, include customized and ready-to-use solutions that span the breadth of the Phoenix platform.
Phoenix is the industry’s premier software platform for managing, analyzing and reporting pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) data. Certara has developed these services to leverage the enormous power of Phoenix by systematizing the “best practices” of its more than 6,000 users and making those practices available to all biopharm organizations.
“Biosimulation has had a profoundly positive impact on drug development and is now expected by global regulators. In fact, 95% of the 45 new drugs approved by the FDA in 2015 used the technology to inform label claims. Additionally, the industry trend is toward moving R&D decision-making around drug viability earlier in the development process and using biosimulation to inform that process,” said Certara Chief Executive Officer Edmundo Muniz, M.D., Ph.D. “The Phoenix Technology Services portfolio is being introduced to help our clients leverage Phoenix software to take advantage of these trends in both preclinical and clinical development.”
Certara is introducing several new services within the Phoenix Technology Services portfolio: